Yvonne Maldonado, MD
Pediatric Infectious Diseases · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Maldonado’s office at (650) 498-5710 to ask if they take your plan before you enroll.
California Medical Board record
Licence G63684 · Current
Licensed to practise in California · since 1988 · expires 2027-10-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$25 in 2025
| 2025 | 1 | 1 | None | $25 |
| 2024 | 1 | 1 | $6,160 | $6,160 |
| 2023 | 1 | 11 | $4,810 | $6,682 |
| 2022 | 1 | 2 | $8,400 | $8,400 |
| 2019 | 1 | 5 | $3,528 | $4,812 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Xospata | $25 | 1 payment
|
See the published payment
| Astellas Pharma US | Meals · 2025-11-04 | Xospata | $25 |
See earlier years (2024, 2023, 2022, 2019)
2024: $6,160
| Pfizer | None | $6,160 | 1 payment
|
2023: $6,682
| Merck Sharp & Dohme | None | $6,682 | 11 payments
|
2022: $8,400
| Pfizer | Trumenba | $8,400 | 2 payments
|
2019: $4,812
| Pfizer | Trumenba | $4,812 | 5 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · Phase 1 Openlabel Dosefinding Study To Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults · 2022 | Their institution | $1,974,070 |
| PFIZER INC. · Phase 1 Openlabel Dosefinding Study To Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults · 2021 | Their institution | $918,145 |
| PFIZER INC. · A Phase 3 Randomized Doubleblinded Placebocontrolled Trial To Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus Rsv Prefusion F Subunit Vaccine in Infants Born To Women Vaccinated During Pregnancy · 2022 | Their institution | $345,792 |
| PFIZER INC. · Phase 1 Openlabel Dosefinding Study To Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults · 2023 | Their institution | $327,329 |
| PFIZER INC. · A Master Phase 123 Protocol To Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children · 2023 | Their institution | $301,991 |
| PFIZER INC. · A Master Phase 123 Protocol To Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children · 2022 | Their institution | $267,844 |
| PFIZER INC. · A Phase 12 Randomized Observerblind Study To Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Varicella Zoster Virus in Healthy Individuals · 2023 | Their institution | $256,117 |
| PFIZER INC. · A Phase 3 Randomized Doubleblinded Placebocontrolled Trial To Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus Rsv Prefusion F Subunit Vaccine in Infants Born To Women Vaccinated During Pregnancy · 2021 | Their institution | $108,333 |
| PFIZER INC. · A Master Phase 123 Protocol To Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children · 2024 | Their institution | $99,096 |
| PFIZER INC. · A Phase 3 Randomized Doubleblinded Placebocontrolled Trial To Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus Rsv Prefusion F Subunit Vaccine in Infants Born To Women Vaccinated During Pregnancy · 2020 | Their institution | $69,169 |
| PFIZER INC. · Phase 1 Openlabel Dosefinding Study To Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults · 2024 | Their institution | $63,182 |
| PFIZER INC. · A Phase 1 Openlabel Agedescending Dosefinding Study and A Phase 23 Placebocontrolled Randomized Doubleblind Study To Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine Rsvpref in Children 2 To 18 Years of Age at High Risk of Rsv Disease · 2023 | Their institution | $53,632 |
| PFIZER INC. · A Phase 3 Randomized Doubleblinded Placebocontrolled Trial To Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus Rsv Prefusion F Subunit Vaccine in Infants Born To Women Vaccinated During Pregnancy · 2023 | Their institution | $31,284 |
| AstraZeneca Pharmaceuticals LP · Open-Label, Uncontrolled, Single Dose Study To Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Azd7442 in Pediatric Participants Aged ? 29 Weeks Gestational Age To < 18 Years · 2023 | Their institution | $27,447 |
| PFIZER INC. · A Phase 1 Openlabel Agedescending Dosefinding Study and A Phase 23 Placebocontrolled Randomized Doubleblind Study To Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine Rsvpref in Children 2 To 18 Years of Age at High Risk of Rsv Disease · 2024 | Their institution | $13,507 |
| PFIZER INC. · A Phase 12 Randomized Observerblind Study To Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Varicella Zoster Virus in Healthy Individuals · 2024 | Their institution | $12,046 |
| PFIZER INC. · A Master Phase 123 Protocol To Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children · 2025 | Their institution | $10,847 |
| PFIZER INC. · Bnt162 Clinical Publication Program · 2022 | This clinician | $3,200 |
| PFIZER INC. · Covid19 Vacc Clinical Publication Program · 2021 | This clinician | $3,200 |
| PFIZER INC. · A Phase 3 Randomized Doubleblinded Placebocontrolled Trial To Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus Rsv Prefusion F Subunit Vaccine in Infants Born To Women Vaccinated During Pregnancy · 2024 | Their institution | $1,748 |
Professional record
- NPI
- 1467598482
- Licence
- CA G63684California G63684: Current · expires 2027-10-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0208X (2080P0208X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2007-01-29
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.